Heiko Stino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heiko Stino has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Pollreisz
Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
13 shared publications - Ursula Schmidt-Erfurth
Medical University of Vienna
8 shared publications - Irene Steiner
Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, 1090 Vienna, Austria
5 shared publications - Kim Lien Huber
Department of Ophthalmology, Medical University of Vienna, 1090 Vienna, Austria
5 shared publications - Stefan Sacu
Department of Ophthalmology Medical University of Vienna Vienna Austria
5 shared publications Tilman Schmoll
Carl Zeiss Meditec Inc., Dublin, USA
5 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Wiley in Acta Ophthalmologica
Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema
Purpose: To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. Methods: This retrospective study at the Medical University of Vienna included patients with DME who were switched from aflibercept 2 mg to faricimab. IRF dynamics and central subfield thickness (CST) were assessed after two faricimab injections. Eyes were categorized as prior responders or non‐responders based on their anatomical response to the last aflibercept injection (≥20% CST reduction or CST ≤250 μm). Optical coherence tomography (OCT)–derived CST and quantitative IRF volumes were analysed at baseline and after two faricimab injections. Associations between CST and IRF changes were evaluated. Results: Fifty‐eight eyes of 45 patients (mean age 65.3 ± 10 years) were included, with 56 eyes previously treated with aflibercept. After two faricimab injections (mean follow‐up 10.1 ± 2.2 weeks), CST and total IRF volume decreased significantly ( p < 0.0001). CST reduction was strongly associated with IRF reduction in the central millimetre (estimate 1.00 [0.73–1.28], p < 0.0001), but less so with total IRF volume (estimate 0.22 [0.17–0.28], p < 0.0001). Responders ( n = 28) showed greater CST reduction compared to non‐responders (−105.6 ± 123.9 μm vs. −27.3 ± 60.1 μm; p = 0.0003) and lower total IRF volume after treatment ( p = 0.029), with more consistent regional improvements. Non‐responders showed smaller but still significant IRF reductions. Conclusions: Switching from aflibercept 2 mg to faricimab resulted in significant reductions in CST and IRF volumes after two injections with a more pronounced effect in previous responders. While CST closely reflected central changes, its weaker association with total IRF reduction indicates that quantitative fluid assessment may further refine evaluation of treatment response and retreatment decisions.
- 14 November 2026
- Published by Wiley in Acta Ophthalmologica
Open AccessEarly intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema
Purpose: To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. Methods: This retrospective study at the Medical University of Vienna included patients with DME who were switched from aflibercept 2 mg to faricimab. IRF dynamics and central subfield thickness (CST) were assessed after two faricimab injections. Eyes were categorized as prior responders or non‐responders based on their anatomical response to the last aflibercept injection (≥20% CST reduction or CST ≤250 μm). Optical coherence tomography (OCT)–derived CST and quantitative IRF volumes were analysed at baseline and after two faricimab injections. Associations between CST and IRF changes were evaluated. Results: Fifty‐eight eyes of 45 patients (mean age 65.3 ± 10 years) were included, with 56 eyes previously treated with aflibercept. After two faricimab injections (mean follow‐up 10.1 ± 2.2 weeks), CST and total IRF volume decreased significantly ( p < 0.0001). CST reduction was strongly associated with IRF reduction in the central millimetre (estimate 1.00 [0.73–1.28], p < 0.0001), but less so with total IRF volume (estimate 0.22 [0.17–0.28], p < 0.0001). Responders ( n = 28) showed greater CST reduction compared to non‐responders (−105.6 ± 123.9 μm vs. −27.3 ± 60.1 μm; p = 0.0003) and lower total IRF volume after treatment ( p = 0.029), with more consistent regional improvements. Non‐responders showed smaller but still significant IRF reductions. Conclusions: Switching from aflibercept 2 mg to faricimab resulted in significant reductions in CST and IRF volumes after two injections with a more pronounced effect in previous responders. While CST closely reflected central changes, its weaker association with total IRF reduction indicates that quantitative fluid assessment may further refine evaluation of treatment response and retreatment decisions.
- Open Access
- 15 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6319
Dynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab
Background/Objectives: Diabetic macular edema is caused by disruptions in the blood–retinal barrier, resulting in leakage and inflammation, appearing in optical coherence tomography as retinal fluid, hard exudates, and hyper-reflective foci. This study aimed to assess volumetric changes in hyper-reflective foci and hard exudates in faricimab-treated diabetic macular edema in real-world practice. Methods: This retrospective longitudinal study included forty-four eyes with faricimab-treated diabetic macular edema and follow-up of ≥40 weeks. Optical coherence tomography scans were analyzed at baseline, post-loading, 6 months and 1 year. Hyper-reflective foci and hard exudates were quantified across macular subfields using a machine-learning algorithm with manual correction. Outcomes included volumetric changes, best-corrected visual acuity, and central subfield thickness. Early morphologic responders were defined post-loading by ≥20% central subfield thickness reduction and/or central subfield thickness below 280 µm. Results: At 1 year, hyper-reflective foci and hard exudate volumes significantly decreased in the central subfield (median differences: −0.025 nL, p = 0.00028; −0.119 nL, p = 0.00025) and outer ring (−0.178 nL, p = 0.00041; −0.612 nL, p = 0.014). Hard exudate volume significantly decreased in the inner ring (−0.740 nL, p < 0.0001). Best-corrected visual acuity and central subfield thickness improved significantly (−0.10 logarithm of the minimum angle of resolution (logMAR), p = 0.0018; −48 µm, p < 0.0001). Total hyper-reflective foci volumes were similar between responders and non-responders. In contrast, hard exudate burden remained numerically higher in non-responders. Conclusions: During the year following the switch to faricimab, HRF and HE burden decreased alongside visual and anatomical improvement. HRF volumes were descriptively similar between early CST responders and non-responders, whereas HE burden remained numerically higher in non-responders.
- 15 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6319
Open AccessDynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab
Background/Objectives: Diabetic macular edema is caused by disruptions in the blood–retinal barrier, resulting in leakage and inflammation, appearing in optical coherence tomography as retinal fluid, hard exudates, and hyper-reflective foci. This study aimed to assess volumetric changes in hyper-reflective foci and hard exudates in faricimab-treated diabetic macular edema in real-world practice. Methods: This retrospective longitudinal study included forty-four eyes with faricimab-treated diabetic macular edema and follow-up of ≥40 weeks. Optical coherence tomography scans were analyzed at baseline, post-loading, 6 months and 1 year. Hyper-reflective foci and hard exudates were quantified across macular subfields using a machine-learning algorithm with manual correction. Outcomes included volumetric changes, best-corrected visual acuity, and central subfield thickness. Early morphologic responders were defined post-loading by ≥20% central subfield thickness reduction and/or central subfield thickness below 280 µm. Results: At 1 year, hyper-reflective foci and hard exudate volumes significantly decreased in the central subfield (median differences: −0.025 nL, p = 0.00028; −0.119 nL, p = 0.00025) and outer ring (−0.178 nL, p = 0.00041; −0.612 nL, p = 0.014). Hard exudate volume significantly decreased in the inner ring (−0.740 nL, p < 0.0001). Best-corrected visual acuity and central subfield thickness improved significantly (−0.10 logarithm of the minimum angle of resolution (logMAR), p = 0.0018; −48 µm, p < 0.0001). Total hyper-reflective foci volumes were similar between responders and non-responders. In contrast, hard exudate burden remained numerically higher in non-responders. Conclusions: During the year following the switch to faricimab, HRF and HE burden decreased alongside visual and anatomical improvement. HRF volumes were descriptively similar between early CST responders and non-responders, whereas HE burden remained numerically higher in non-responders.
- Open Access
- 13 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3747
First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria
Background: Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME. Methods: We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid. Results: Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN. Conclusions: First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.
- 13 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3747
Open AccessFirst-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria
Background: Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME. Methods: We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid. Results: Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN. Conclusions: First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.
- Open Access
- 3 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Label-free in vivo molecular profiling of the human retina by non-resonant Raman spectroscopy
Early detection of retinal molecular biomarkers is crucial for addressing the unmet clinical need to prevent irreversible neural tissue damage in ophthalmic and neurodegenerative diseases. Among emerging molecular sensing techniques, non-resonant Raman spectroscopy stands out as a naturally label-free and noninvasive method, offering rich biochemical information. However, in vivo detection of non-resonant Raman spectra from retinal tissue has proven to be challenging so far. Previous studies have reported conflicting results, likely due to overwhelming pigment autofluorescence. In this study, we identified the optic nerve head as the optimal retinal location for acquiring non-resonant Raman spectra in the molecular fingerprint region. Through longitudinal intra-subject measurements, we revealed dynamic changes in the molecular composition. Furthermore, a comparative study across age groups enabled the identification of molecular alterations associated with aging. These findings establish a critical foundation for utilizing non-resonant Raman spectroscopy as an early diagnostic tool for the detection of molecular biomarkers associated with ophthalmic and neurodegenerative diseases.
- 3 March 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessLabel-free in vivo molecular profiling of the human retina by non-resonant Raman spectroscopy
Early detection of retinal molecular biomarkers is crucial for addressing the unmet clinical need to prevent irreversible neural tissue damage in ophthalmic and neurodegenerative diseases. Among emerging molecular sensing techniques, non-resonant Raman spectroscopy stands out as a naturally label-free and noninvasive method, offering rich biochemical information. However, in vivo detection of non-resonant Raman spectra from retinal tissue has proven to be challenging so far. Previous studies have reported conflicting results, likely due to overwhelming pigment autofluorescence. In this study, we identified the optic nerve head as the optimal retinal location for acquiring non-resonant Raman spectra in the molecular fingerprint region. Through longitudinal intra-subject measurements, we revealed dynamic changes in the molecular composition. Furthermore, a comparative study across age groups enabled the identification of molecular alterations associated with aging. These findings establish a critical foundation for utilizing non-resonant Raman spectroscopy as an early diagnostic tool for the detection of molecular biomarkers associated with ophthalmic and neurodegenerative diseases.
- Open Access
- 3 March 2026
- Published by Springer Nature in Eye
- Vol. 40 (8) , 1121-1127
Evaluation of photoreceptor integrity in diabetic retinopathy using high-resolution optical coherence tomography
Background: The relative ellipsoid zone reflectivity (rEZR) is a promising imaging biomarker for photoreceptor integrity, but its variation across diabetic retinopathy (DR) stages remains unclear. This study investigates rEZR changes across different DR severities using high-resolution optical coherence tomography (OCT) imaging. Methods: For this exploratory cross-sectional study, 64 eyes of 44 patients were included (17 eyes: no DR, 33 eyes: non-proliferative DR (NPDR), 14 eyes: proliferative DR (PDR)). Imaging was performed using high-resolution spectral-domain OCT (SPECTRALIS HighRes OCT, Heidelberg Engineering, axial resolution: 3 μm). rEZR (ratio between ellipsoid zone and external limiting membrane reflectivity) was measured at the foveola, within the Early Treatment Diabetic Retinopathy Study ETDRS grid (central 1 mm, inner ring, outer ring) and peripapillary. Linear mixed models assessed the association between rEZR, DR stage and visual acuity. Results: In the outer macular ring, mean rEZR was significantly lower in PDR compared to no DR ( p = 0.005) and NPDR ( p = 0.045). In the total area, mean rEZR was significantly lower in PDR compared to no DR ( p = 0.016) and NPDR ( p = 0.032). Peripapillary mean rEZR was significantly lower in NPDR compared to no DR ( p = 0.013) and in PDR compared to no DR ( p = 0.033). No significant group differences were observed in the foveola, central 1 mm or inner macular ring. Conclusion: Our data suggest that more advanced stages of DR are associated with a decrease in photoreceptor integrity, with statistically significant group differences predominantly observed in the outer macular regions and peripapillary.
- 3 March 2026
- Published by Springer Nature in Eye
- Vol. 40 (8) , 1121-1127
Open AccessEvaluation of photoreceptor integrity in diabetic retinopathy using high-resolution optical coherence tomography
Background: The relative ellipsoid zone reflectivity (rEZR) is a promising imaging biomarker for photoreceptor integrity, but its variation across diabetic retinopathy (DR) stages remains unclear. This study investigates rEZR changes across different DR severities using high-resolution optical coherence tomography (OCT) imaging. Methods: For this exploratory cross-sectional study, 64 eyes of 44 patients were included (17 eyes: no DR, 33 eyes: non-proliferative DR (NPDR), 14 eyes: proliferative DR (PDR)). Imaging was performed using high-resolution spectral-domain OCT (SPECTRALIS HighRes OCT, Heidelberg Engineering, axial resolution: 3 μm). rEZR (ratio between ellipsoid zone and external limiting membrane reflectivity) was measured at the foveola, within the Early Treatment Diabetic Retinopathy Study ETDRS grid (central 1 mm, inner ring, outer ring) and peripapillary. Linear mixed models assessed the association between rEZR, DR stage and visual acuity. Results: In the outer macular ring, mean rEZR was significantly lower in PDR compared to no DR ( p = 0.005) and NPDR ( p = 0.045). In the total area, mean rEZR was significantly lower in PDR compared to no DR ( p = 0.016) and NPDR ( p = 0.032). Peripapillary mean rEZR was significantly lower in NPDR compared to no DR ( p = 0.013) and in PDR compared to no DR ( p = 0.033). No significant group differences were observed in the foveola, central 1 mm or inner macular ring. Conclusion: Our data suggest that more advanced stages of DR are associated with a decrease in photoreceptor integrity, with statistically significant group differences predominantly observed in the outer macular regions and peripapillary.
- Open Access
- 23 March 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (5) , 297-305
Correlation of point-wise retinal sensitivity with localized features of diabetic macular edema using deep learning
- 23 March 2025
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (5) , 297-305
Open AccessCorrelation of point-wise retinal sensitivity with localized features of diabetic macular edema using deep learning
- Open Access
- 28 August 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (3) , e443-e450
Association of microaneurysms with retinal vascular alterations in patients with retinal vein occlusion
- 28 August 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (3) , e443-e450
Open AccessAssociation of microaneurysms with retinal vascular alterations in patients with retinal vein occlusion
- Open Access
- 21 December 2023
- Published by Wiley in Acta Ophthalmologica
- Vol. 102 (5) , e687-e695
Microaneurysm detection using high‐speed megahertz optical coherence tomography angiography in advanced diabetic retinopathy
Purpose: To compare detection rates of microaneurysms (MAs) on high‐speed megahertz optical coherence tomography angiography (MHz‐OCTA), fluorescein angiography (FA) and colour fundus photography (CF) in patients with diabetic retinopathy (DR).Methods: For this exploratory cross‐sectional study, MHz‐OCTA data were acquired with a swept‐source OCT prototype (A‐scan rate: 1.7 MHz), and FA and CF imaging was performed using Optos® California. MA count was manually evaluated on en face MHz‐OCTA/FA/CF images within an extended ETDRS grid. Detectability of MAs visible on FA images was evaluated on corresponding MHz‐OCTA and CF images. MA distribution and leakage were correlated with detectability on OCTA and CF imaging.Results: 47 eyes with severe DR (n = 12) and proliferative DR (n = 35) were included. MHz‐OCTA and CF imaging detected on average 56% and 36% of MAs, respectively. MHz‐OCTA detection rate was significantly higher than CF (p < 0.01). The combination of MHz‐OCTA and CF leads to an increased detection rate of 70%. There was no statistically significant association between leakage and MA detectability on OCTA (p = 0.13). For CF, the odds of detecting leaking MAs were significantly lower than non‐leaking MAs (p = 0.012). Using MHz‐OCTA, detection of MAs outside the ETDRS grid was less likely than MAs located within the ETDRS grid (outer ring, p < 0.01; inner ring, p = 0.028). No statistically significant difference between rings was observed for CF measurements.Conclusions: More MAs were detected on MHz‐OCTA than on CF imaging. Detection rate was lower for MAs located outside the macular region with MHz‐OCTA and for leaking MAs with CF imaging. Combining both non‐invasive modalities can improve MA detection.
- 21 December 2023
- Published by Wiley in Acta Ophthalmologica
- Vol. 102 (5) , e687-e695
Open AccessMicroaneurysm detection using high‐speed megahertz optical coherence tomography angiography in advanced diabetic retinopathy
Purpose: To compare detection rates of microaneurysms (MAs) on high‐speed megahertz optical coherence tomography angiography (MHz‐OCTA), fluorescein angiography (FA) and colour fundus photography (CF) in patients with diabetic retinopathy (DR).Methods: For this exploratory cross‐sectional study, MHz‐OCTA data were acquired with a swept‐source OCT prototype (A‐scan rate: 1.7 MHz), and FA and CF imaging was performed using Optos® California. MA count was manually evaluated on en face MHz‐OCTA/FA/CF images within an extended ETDRS grid. Detectability of MAs visible on FA images was evaluated on corresponding MHz‐OCTA and CF images. MA distribution and leakage were correlated with detectability on OCTA and CF imaging.Results: 47 eyes with severe DR (n = 12) and proliferative DR (n = 35) were included. MHz‐OCTA and CF imaging detected on average 56% and 36% of MAs, respectively. MHz‐OCTA detection rate was significantly higher than CF (p < 0.01). The combination of MHz‐OCTA and CF leads to an increased detection rate of 70%. There was no statistically significant association between leakage and MA detectability on OCTA (p = 0.13). For CF, the odds of detecting leaking MAs were significantly lower than non‐leaking MAs (p = 0.012). Using MHz‐OCTA, detection of MAs outside the ETDRS grid was less likely than MAs located within the ETDRS grid (outer ring, p < 0.01; inner ring, p = 0.028). No statistically significant difference between rings was observed for CF measurements.Conclusions: More MAs were detected on MHz‐OCTA than on CF imaging. Detection rate was lower for MAs located outside the macular region with MHz‐OCTA and for leaking MAs with CF imaging. Combining both non‐invasive modalities can improve MA detection.
- Open Access
- 24 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5493
Macular Microvascular Perfusion Status in Hypertensive Patients with Chronic Kidney Disease
To compare retinal microvascular perfusion between the eyes of hypertensive patients with and without chronic kidney disease (CKD), the vessel density (VD) and fractal dimension (FD) of the superficial (SVP) and deep retinal vascular plexus (DVP) were analyzed on 6 × 6 mm fovea-centered optical coherence tomography angiography (OCTA) images of patients with hypertension. The retina was divided into an inner ring (IR) and outer ring (OR) according to the Early Treatment of Diabetic Retinopathy Study grid. The glomerular filtration rate (GFR) was determined and CKD was diagnosed (GFR < 60 mL/min/1.73 m2). Ninety-six eyes from 52 patients with hypertension were included in this analysis. Twenty patients (n = 37 eyes) were diagnosed with CKD. The mean age was 69 ± 11.7 years and 60.4 ± 9.2 years in the CKD group and in the control group, respectively. The univariate model revealed a significant difference in VD between patients without and with CKD in the superficial IR (0.36 ± 0.03 vs. 0.34 ± 0.04, p = 0.03), the superficial OR (0.35 ± 0.02 vs. 0.33 ± 0.04, p = 0.02), the deep OR (0.24 ± 0.01 vs. 0.23 ± 0.02, p = 0.003), and the FD in the SVP (1.87 ± 0.01 vs. 1.86 ± 0.02, p = 0.02) and DVP (1.83 ± 0.01 vs. 1.82 ± 0.01, p = 0.006). After adjusting for age and sex, these differences did not remain statistically significant. Similar results were observed for the FD in the SVP and DVP. In our cohort, patients with hypertension and CKD did not differ from patients without CKD in regard to microvascular perfusion status in the macular area as assessed using OCTA.
- 24 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5493
Open AccessMacular Microvascular Perfusion Status in Hypertensive Patients with Chronic Kidney Disease
To compare retinal microvascular perfusion between the eyes of hypertensive patients with and without chronic kidney disease (CKD), the vessel density (VD) and fractal dimension (FD) of the superficial (SVP) and deep retinal vascular plexus (DVP) were analyzed on 6 × 6 mm fovea-centered optical coherence tomography angiography (OCTA) images of patients with hypertension. The retina was divided into an inner ring (IR) and outer ring (OR) according to the Early Treatment of Diabetic Retinopathy Study grid. The glomerular filtration rate (GFR) was determined and CKD was diagnosed (GFR < 60 mL/min/1.73 m2). Ninety-six eyes from 52 patients with hypertension were included in this analysis. Twenty patients (n = 37 eyes) were diagnosed with CKD. The mean age was 69 ± 11.7 years and 60.4 ± 9.2 years in the CKD group and in the control group, respectively. The univariate model revealed a significant difference in VD between patients without and with CKD in the superficial IR (0.36 ± 0.03 vs. 0.34 ± 0.04, p = 0.03), the superficial OR (0.35 ± 0.02 vs. 0.33 ± 0.04, p = 0.02), the deep OR (0.24 ± 0.01 vs. 0.23 ± 0.02, p = 0.003), and the FD in the SVP (1.87 ± 0.01 vs. 1.86 ± 0.02, p = 0.02) and DVP (1.83 ± 0.01 vs. 1.82 ± 0.01, p = 0.006). After adjusting for age and sex, these differences did not remain statistically significant. Similar results were observed for the FD in the SVP and DVP. In our cohort, patients with hypertension and CKD did not differ from patients without CKD in regard to microvascular perfusion status in the macular area as assessed using OCTA.
- Open Access
- 28 July 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (12) , 1042-1050
Association of Diabetic Lesions and Retinal Nonperfusion Using Widefield Multimodal Imaging
- 28 July 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (12) , 1042-1050
Open AccessAssociation of Diabetic Lesions and Retinal Nonperfusion Using Widefield Multimodal Imaging